Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Xeris Biopharma Holdings (XERS) Other Non Operating Income: 2020-2025

Historic Other Non Operating Income for Xeris Biopharma Holdings (XERS) over the last 5 years, with Sep 2025 value amounting to -$6.1 million.

  • Xeris Biopharma Holdings' Other Non Operating Income rose 0.96% to -$6.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$25.4 million, marking a year-over-year decrease of 24.40%. This contributed to the annual value of -$23.5 million for FY2024, which is 20.33% down from last year.
  • Per Xeris Biopharma Holdings' latest filing, its Other Non Operating Income stood at -$6.1 million for Q3 2025, which was up 4.68% from -$6.4 million recorded in Q2 2025.
  • In the past 5 years, Xeris Biopharma Holdings' Other Non Operating Income registered a high of $1.9 million during Q4 2022, and its lowest value of -$7.6 million during Q3 2023.
  • Its 3-year average for Other Non Operating Income is -$5.6 million, with a median of -$6.1 million in 2025.
  • Over the last 5 years, Xeris Biopharma Holdings' Other Non Operating Income had its largest YoY gain of 175.51% in 2022, and its largest YoY loss of 340.28% in 2022.
  • Over the past 5 years, Xeris Biopharma Holdings' Other Non Operating Income (Quarterly) stood at -$2.5 million in 2021, then spiked by 175.51% to $1.9 million in 2022, then crashed by 299.00% to -$3.8 million in 2023, then slumped by 79.45% to -$6.8 million in 2024, then rose by 0.96% to -$6.1 million in 2025.
  • Its Other Non Operating Income stands at -$6.1 million for Q3 2025, versus -$6.4 million for Q2 2025 and -$6.1 million for Q1 2025.